Summary: This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and with metasta...
Summary: Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine call...
Summary: This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity...
Summary: This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD dose...
Summary: This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient c...
Summary: This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhi...
Summary: This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer...
Summary: Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma....
Summary: The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone...
Summary: The purpose of this study is to assess whether the combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI i...
Summary: The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (...
Summary: Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC).mCRPC is a cancer of...
Summary: This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, ...
Summary: Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male se...
The primary objective of this clinical trial is to assess the effcacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.
VISIT
This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.
VISIT
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) in Men With Hormone Sensitive Prostate Cancer and Rise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)
VISIT
The primary goal of this clinical trial is to determine if adding mevrometostat to the standard therapy (enzalutamide) is more effective in treating metastatic castration-sensitive prostate cancer compared to enzalutamide alone with a placebo.
VISIT
The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide…
VISIT
The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
VISIT
